Market Overview

Parkinson's Disease Market 2018 by Phase of Development, Type of Treatment, Type of Molecule, Mechanism of Action, Route of Administration, and Leading Players


Parkinson's Disease Market 2018 by Phase of Development, Type of Treatment, Type of Molecule, Mechanism of Action, Route of Administration, and Leading Players

PR Newswire

DUBLIN, Aug. 1, 2018 /PRNewswire/ --

The "Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights" report has been added to's offering.

Research and Markets Logo

Parkinson's disease is a chronic disorder that gradually leads to progressive deterioration of motor functions due to loss of dopamine-producing brain cells. It is presently the second most common neurodegenerative disease (after Alzheimer's disease) and is characterized by symptoms such as shaking, rigidity, difficulty in walking / movement, and several other cognitive and behavioral problems. Parkinson's disease is known to affect 1-2 per 1,000 individuals and has been shown to impact approximately 1% of the population aged above 60 years. It is also worth highlighting that, every year, nearly 60,000 Americans are diagnosed with Parkinson's.

The disease has been estimated to incur combined direct and indirect costs of close to USD 25 billion in the US annually. With increasing disease prevalence and the corresponding growth in socioeconomic burden, the field faces a pressing need for accurate diagnostic (predictive) tests, and efficient treatment options for slowing the progression of the disease. Despite the availability of several types of dopamine agonists, there still are a myriad of motor and non-motor symptoms that currently available therapies are unable to treat.

The unavailability of neuroprotective therapies remains one of the prime unmet needs in this domain. The disease is highly complex and is known to render any single therapeutic approach inadequate to deal with its multifaceted etiopathogenesis. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to advance the development of various types of disease modifying pharmacological interventions, therapies to offer symptomatic relief and drugs to try to cure the disease as well. In fact, there are multiple initiatives established by start-ups that are being backed by venture capital funding to expedite the development of potential therapeutic options for better disease management.

Amongst other elements, the report includes:

A detailed assessment of the current market landscape of drugs being developed for the treatment of Parkinson's disease, providing information on drug developer(s), phase of development (clinical, preclinical / discovery stage) of product candidates, type of molecule (small molecule, biologic or gene / cell therapy), treatment type (disease modifying agent, drugs offering symptomatic relief or drugs for curing the disease), mechanism of action, and route of administration.

An in-depth analysis of the product pipeline and developer companies, featuring four schematic representations; these include [A] a heptagon representation highlighting the distribution of the marketed and development stage molecules based on their mechanisms of action, [B] a 2X2 grid analysis, representing the distribution of drug candidates across various molecule types and stages of development, [C] a funnel analysis highlighting the distribution of molecules (segregated by stage of development) based on route of administration and treatment type, and [D] a logo landscape of the various industry players involved in the development of drugs, distributed on the basis of location of headquarters and company size (small-sized, mid-sized and large).

An analysis highlighting the key unmet needs across Parkinson's disease, featuring insights generated from real-time data on unmet needs as identified from social media posts, recent publications, patient blogs and the views of key opinion leaders expressed on online platforms.

Comprehensive profiles of drugs in phase III of clinical development, with information on the developer, specific target patient population, mechanism of action, clinical trials, current status of development, and recent developments (if available).

An insightful competitive analysis, highlighting the key players in the domain on the basis of the strength of their development portfolio. For all companies that emerged as important players in this field, we have presented a five-dimensional spider web analysis, taking into account the company's size, activity on Google Trends, stage of development of lead molecule, strength of the Parkinson's disease pipeline and the (present) number of clinical trials being conducted by the player.

A detailed analysis of the mergers and acquisitions that have taken place in this space, highlighting the trend in the number of companies acquired in the last few years, along with the geographical distribution of this activity. The analysis features an ownership change matrix and presents a financial evaluation of these deals (revenues and respective deal multiples) as well.

A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers involved in the development of molecules in this domain.

An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.

A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in development of anti-Parkinson's therapeutics.

Example Highlights

The analysis of content presented on informal (50 patient blogs and over 12,000 social media posts) and formal (over 200 scientific literature studies) literary sources, and the opinions express by industry experts confirm the existence of a significant unmet need within the anti-Parkinson's disease therapeutics market. Some of the unaddressed concerns suggested through multiple portals include lack of disease modifying treatments, delayed diagnosis, unavailability of therapies to manage non-motor symptoms and poor quality of life.

Over 180 product candidates are currently being evaluated across various stages of development for the management / treatment of Parkinson's disease. Of these, 55% are in the preclinical or discovery phase. Amongst the drugs that are under clinical development, 7 are in phase III, 42 in phase II, and 25 in phase I and phase I/II trials. Interestingly, since 2015, four product candidates have been approved; these are (based on year of approval) OSMOLEX ER (2018), NUPLAZID (2016), ONGENTYS (2016) and Xadago (2015).

Majority of novel drugs (53%) are disease modifying agents, while 32% of candidate molecules are being developed for providing symptomatic relief only. Rest of the drugs are designed and being evaluated to cure Parkinson's disease. It is worth highlighting that 34% of pipeline candidates have been shown to induce therapeutic effect by inhibiting a protein / enzyme; further, 17% are dopamine agonists, while 13% are channel / receptor antagonists.

The market landscape is characterized by the presence of large (20), mid-sized (31) and small-sized companies (91). Some of the prominent large companies engaged in this domain include (in alphabetical order, no selection criteria) AbbVie, ACADIA Pharmaceuticals, Amgen, AstraZeneca, BIAL Group, Eli Lilly, Lundbeck, Luye Pharmaceuticals, Osmotica Pharmaceutical, Sumitomo Dainippon Pharma, UCB Pharma and Zambon. The growing unmet need within this domain has spurred the establishment of many start-ups in the recent years; examples include (in alphabetical order, no selection criteria) 4P Therapeutics, Acelot, Aeolus Pharmaceuticals, Aestas Pharma, Antoxis, BlueRock Therapeutics, BrainStorm Cell Therapeutics, Capo Therapeutics, Cellix Bio, Cerevance, Clera, Contera Pharma, Curemark, DermaXon, Domain Therapeutics, Enterin, Fabre-Kramer Pharmaceuticals, Herantis Pharma Impel NeuroPharma, Io Therapeutics, Junaxo, Living Cell Technologies, Lysosomal Therapeutics, Melior Pharmaceuticals, Minerave Neurosciences, Mission Therapeutics, Peptron, Pharma Two B, Prana Biotechnology, Priavoid, Primary Peptides, QR Pharma, Serina Therapeutics, TechnoPhage, Vivreon Biosciences and Xoc Pharmaceuticals.

More than USD 2.2 billion has been invested in various companies, across 182 instances of funding, since 2010. The Michael J. Fox Foundation, Vinnova, Roche Venture Fund, Mrieux Dveloppement, Alliance of Angels, Shire, Ysios Capital, Third Rock Ventures, Takeda Pharmaceutical, Sunstone Capital and Sofinnova Partners have emerged as some of the prominent investors (in terms of number of funding instances) in this market.

Several prominent scientists (over 100 investigators evaluated) have made significant contributions in advancing the clinical development efforts and, therefore, have emerged as key opinion leaders in this field. It is worth noting that universities and hospitals, across various regions, have been conducting breakthrough research along with various KOLs to develop an efficient treatment for patients with Parkinson's disease; examples of these universities and hospitals are (in alphabetical order, no selection criteria) Addenbrookes Hospital, Auckland City Hospital, Cedars-Sinai Medical Center, Jichi Medical University and Loma Linda University of Health.

The domain has witnessed over seven acquisitions in the recent past, highlighting that the market is partly driven by acquisition of start-ups with promising drug candidates. These include multiple big-ticket deals; a prominent example being the acquisition of Prexton Therapeutics by Lundbeck (deal valued at USD 1.1 billion) in March 2018. Interestingly, majority of the acquisition events took place in the US; however, there were several cross-border acquisitions involving start-ups based in the US and big pharmaceutical players in Japan.

Key Topics Covered

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines


3.1. An Overview of Parkinson's Disease
3.1.1. History and Causes
3.1.2. Symptoms
3.1.3. Epidemiology
3.1.4. Economic Burden
3.2. Parkinson's Disease Management
3.2.1. Pharmacological Management of Parkinson's Disease
3.2.2. Non-Pharmacological Management of Parkinson's Disease
3.2.3. Management of Parkinson's Disease Using Dietary Supplements
3.2.4. Convenient Remedies to Manage Parkinson's Disease

4.1. Chapter Overview
4.2. Parkinson's Disease: Marketed and Development Pipeline
4.3. Parkinson's Disease: Pipeline Analysis
4.3.1. Distribution by Phase of Development
4.3.2. Distribution by Type of Treatment
4.3.3. Distribution by Type of Molecule
4.3.4. Distribution by Mechanism of Action
4.3.5. Distribution by Route of Administration
4.3.6. Distribution by Leading Players
4.3.7. Funnel Analysis: Distribution by Phase of Development, Treatment Type and Route of Administration
4.3.8. Heptagon Representation: Distribution by Mechanism of Action and Phase of Development
4.3.9. Grid Analysis: Distribution by Type of Molecule and Phase of Development
4.3.10. Developer Logo Landscape: Distribution by Company Size and Location

5.1. Chapter Overview
5.2. Unmet Need Analysis for Parkinson's Disease
5.2.1. Analysis Overview
5.2.2. Blogposts by Patients Methodology Affiliated Insights
5.2.3. Published Literature Methodology Affiliated Insights
5.2.4. Social Media Platforms Methodology Affiliated Insights
5.2.5. Expert Opinions Rajesh Pahwa, University of Kansas Medical Center, US V Natarajan, Professor of Neurology, Institute of Neurology, Madras Medical College, India Richard Wade-Martins, Oxford Parkinson's Disease Center (OPDC) Principal Investigator; Michele Hu, OPDC Clinical Lead; Mark Kelly, OPDC; James Cantley, Department of Physiology, Anatomy and Genetics, University of Oxford, UK K Ray Chaudhuri, Professor of Neurology/Movement Disorders at King's College Hospital, UK Daniel M Cocos, Professor of Physical Therapy & Human Movement Sciences, Feinberg School of Medicine, North-eastern University, US Rachel Dolhun, MD, Neurologist and Movement Disorder Specialist, US
5.2.6. Key Unmet Needs in Parkinson's Disease

6.1. Chapter Overview
6.2. Drug Profile: Accordion Pill - Carbidopa / Levodopa (Intec Pharma)
6.3. Drug Profile: APL-130277 / Apomorphine Hydrochloride (Sunovion)
6.4. Drug Profile: Apomorphine Hydrochloride (Britannia Pharmaceuticals)
6.5. Drug Profile: Apomorphine Infusion (US WorldMeds)
6.6. Drug Profile: Istradefylline / KW-6002 (Kyowa Hakko Kirin)
6.7. Drug Profile: ND0612 (NeuroDerm)
6.8. Drug Profile: P2B001 (Pharma Two B)

7.1. Chapter Overview
7.2. Methodology
7.2.1. Assumptions and Key Parameters
7.3. Affiliated Insights
7.3.1. Spider Web Competitive Analysis: AbbVie
7.3.2. Spider Web Competitive Analysis: Acorda Therapeutics
7.3.3. Spider Web Competitive Analysis: Addex Therapeutics
7.3.4. Spider Web Competitive Analysis: Axovant Sciences
7.3.5 Spider Web Competitive Analysis: Integrative Research Laboratories
7.3.6. Spider Web Competitive Analysis: Kyowa Hakko Kirin
7.3.7. Spider Web Competitive Analysis: NeuroDerm
7.3.8. Spider Web Competitive Analysis: Sunovion
7.3.9. Spider Web Competitive Analysis: UCB

8.1. Chapter Overview
8.2. Parkinson's Disease: Mergers and Acquisitions
8.2.1. Mergers and Acquisitions: Analysis by Year
8.2.2. Mergers and Acquisitions: Geographical Activity
8.2.3. Mergers and Acquisitions: Ownership Change Matrix
8.3. Key Acquisitions: Deal Multiples

9.1. Chapter Overview
9.2. Methodology
9.3. Current Researcher Landscape
9.3.1. Prominent Key Opinion Leaders
9.4. Geographical Location of Key Opinion Leaders
9.5. Most Active Key Opinion Leaders
9.5.1. KOL Profile: Robert Hauser, College of Medicine Neurology
9.5.2. KOL Profile: Mika Scheinin, University of Turku

10.1. Chapter Overview
10.2. Types of Funding
10.3. Parkinson's Disease Therapy Developers: Funding and Investment Analysis
10.3.1. Analysis by Cumulative Number of Funding Instances
10.3.2. Analysis by Cumulative Amount Invested
10.3.3 Analysis by Type of Funding
10.3.4 Analysis by Most Active Players
10.3.5. Analysis by Most Active Investors

11.1. Chapter Overview
11.2. Parkinson's Disease Therapeutics: Phase of Development
11.3. Parkinson's Disease Therapeutics: Drug Classes
11.4. Parkinson's Disease Therapeutics: Partnerships
11.5. Parkinson's Disease Therapeutics: Current Market Opportunity
11.6. Parkinson's Disease Therapeutics: Future Market Opportunity



Companies Featured in the Report

  • 3M New Ventures
  • 4P Therapeutics
  • 5AM Ventures
  • Abbott
  • AbbVie
  • AC Immune
  • ACADIA Pharmaceuticals
  • Accera
  • Acelot
  • Acino
  • Acorda Therapeutics
  • Addenbrooke's Hospital
  • Addex Therapeutics
  • Aeolus Pharmaceuticals
  • Aestas Pharma
  • AFFiRiS
  • Alliance of Angels
  • AMAbiotics
  • Amarantus BioScience
  • Amgen
  • aMoon
  • Anavex Life Sciences
  • Antoxis
  • ApoPharma
  • Araclon Biotech
  • ArmaGen
  • Armistice Capital
  • Arrien Pharmaceuticals
  • Asceneuron
  • AstraZeneca
  • Atlas Venture
  • Auckland City Hospital
  • Avanir Pharmaceuticals
  • Avant Diagnostics
  • Axovant Sciences
  • AZTherapies
  • Azur Pharma
  • Babraham Research Campus
  • Bayer
  • Ben Franklin Technology Partners
  • BenevolentAI
  • Bertin Bioreagent
  • BIAL
  • BioAdvance
  • BioArctic
  • BioElectron Technology
  • Biogen
  • BioReference Laboratories
  • Biotie Therapeutics
  • BlueRock Therapeutics
  • Boehringer Ingelheim Venture Fund
  • Bpifrance
  • BrainStorm Cell Therapeutics
  • BrainX
  • Britannia Pharmaceuticals
  • Brookside Capital
  • Bukwang Pharmaceutical
  • Burkina Faso Caisses Populaires
  • BVF Partners
  • Caixa Capital Risc
  • Callaghan Innovation
  • Canadian Institutes of Health Research
  • Cantabio Pharmaceuticals
  • Capo Therapeutics
  • Carna Biosciences
  • Casdin Capital
  • Cedars-Sinai Medical Center
  • Celavie Biosciences
  • Celerion
  • Cellix Bio
  • Centurion Private
  • Cerevance
  • Chelsea Therapeutics
  • Chinese Academy of Sciences
  • Chipscreen Biosciences
  • Clera
  • CleveXel Pharma
  • Clinical Research Services Turku
  • Cobra Biologics
  • Collaborative Medicinal Development
  • Collidion
  • Columbia University Irving Medical Center
  • Commission for Technology and Innovation
  • Contera Pharma
  • Corium
  • Cormorant Asset Management
  • Crossroad FCP
  • Curemark
  • Cynapsus Therapeutics
  • Dart NeuroScience
  • Dementia Discovery Fund
  • Denali Therapeutics
  • DermaXon
  • Desitin Arzneimittel
  • Deutsche Parkinson Vereinigung
  • Discover Growth Fund
  • Domain Therapeutics
  • Dominion Capital
  • Dong-A ST
  • Duke University Health Center
  • Eli Lilly
  • Emory University
  • Enterin
  • Fabre-Kramer Pharmaceuticals
  • Federal University of So Paulo
  • Forbion Capital Partners
  • Friedrich-Baur-Institute
  • Fulcrum Therapeutics
  • Gabriel Capital Management
  • Gene Therapy Research Institution
  • Generali Financial Holdings
  • Genervon Biopharmaceuticals
  • Genomia
  • GlaxoSmithKline
  • GNT Pharma
  • Grampian Biopartners
  • Hammersmith Medicines Research
  • Hatteras Venture Partners
  • HealthEquity
  • Henri Mondor Hospital
  • Henry Ford West Bloomfield Hospital
  • Herantis Pharma
  • Hercules Capital
  • Herculis Partners
  • Highland Capital Management
  • Histostem
  • Hpital Piti-Salptrire
  • Horizon Technology Finance
  • Hospital Angeles Pedregal
  • Hospital Sant Pau
  • Hypnion
  • Idec Pharmaceuticals
  • IIB Sant Pau
  • Immungenetics
  • IMPAX Laboratories
  • Impel NeuroPharma
  • Imperial Innovations
  • Index Ventures
  • Inhibikase Therapeutics
  • Innovate UK
  • Innovative California Biosciences International
  • Intec Pharma
  • Integrative Research Laboratories
  • International Infusion
  • International Stem Cell Corporation
  • Intra-Cellular Therapies
  • Invercaria
  • Io Therapeutics
  • IRCCS Ospedale San Raffaele
  • Israel Biotech Fund
  • Israel Innovation Authority
  • Jazz Pharmaceuticals
  • JEIL Pharmaceutical
  • Jichi Medical University
  • JK&B Capital
  • Johns Hopkins University
  • Johnson & Johnson
  • Junaxo
  • Kainos Medicine
  • Kapital Assets
  • Khondrion
  • KISSEI Pharmaceutical
  • Korea Drug Development Fund
  • K-PAX Pharmaceuticals
  • Kyowa Hakko Kirin
  • Lightstone Ventures
  • Lincoln Park Capital Fund
  • Living Cell Technologies
  • Loma Linda University Health
  • Longevity Biotech
  • LTS Lohmann Therapie-Systeme
  • Luc Therapeutics
  • Lundbeck
  • Luye Pharma Group
  • Lysosomal Therapeutics
  • MedGenesis Therapeutix
  • Medical University of Innsbruck
  • Med-Life Discoveries
  • Melbourne Health
  • Melior Pharmaceuticals
  • Merck Ventures
  • Mrieux Dveloppement
  • Mertz Holdings
  • Metabolic Solutions Development
  • MIG Verwaltungs
  • Minerva Neurosciences
  • Ministry of Health (Brazil)
  • Mission Therapeutics
  • Mitochon Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Mitsui Global Investment
  • Montisera
  • MS Ventures
  • National Institute of Mental Health
  • National Institute of Neurological Disorders and Stroke
  • National Institutes of Health
  • National Science Foundation
  • Netherlands Translational Research Center
  • Neurocrine Biosciences
  • NeuroDerm
  • Neurodyn
  • NeuroGeneration
  • NeuroHealing Pharmaceuticals
  • Neurolixis
  • NeuroNascent
  • NeurOp
  • Neuropore Therapies
  • New World Laboratories
  • Newron Pharmaceuticals
  • NewYork-Presbyterian Hospital
  • Nice & Green
  • nLife Therapeutics
  • NLS Pharma
  • Nordic Life Sciences
  • Novartis
  • Novo Holdings
  • Nutriband
  • NYU Langone Health
  • Oncodesign
  • OPKO Health
  • Oregon Health and Science University
  • Orion
  • Osmotica Pharmaceutical
  • Otsuka Pharmaceuticals
  • Oulu Deaconess Institute
  • Oxalys Pharmaceuticals
  • Oxford BioMedica
  • Partner Fund Management
  • Partners Innovation Fund
  • Peptron
  • Perceptive Advisors
  • Pfizer Venture Investment
  • Pharma Two B
  • Pharnext
  • Plex Pharmaceuticals
  • Plymouth University Peninsula Schools of Medicine and Dentistry
  • Prana Biotechnology
  • Prexton Therapeutics
  • Priavoid
  • Primary Peptides
  • ProbeX
  • Proclara Biosciences
  • ProMIS Neurosciences
  • Promius Pharma
  • Prothena Biosciences
  • QR Pharma
  • Quintiles Transnational
  • RaQualia Pharma
  • Regis Duffy BioScience Fund
  • reMYND
  • Retrotope
  • Roche
  • Rush University Medical Center
  • SAGE Therapeutics
  • SalubRx Therapeutics
  • Saniona
  • Sanofi
  • Santo Venture Capital
  • Scottish Enterprise
  • Seeds Capital
  • Seoul National University Hospital
  • Serina Therapeutics
  • Seroba Life Science
  • S eventure Partners
  • Shire
  • SK Biopharmaceuticals
  • Sodiv
  • Sofinnova Partners
  • Solstice Neurosciences
  • Sphera Global Healthcare Fund
  • SR One
  • STADA Arzneimittel
  • StrataGent Life Sciences
  • Sumitomo Dainippon Pharma
  • Sun Pharma Advanced Research Company
  • Sunovion
  • Sunstone Capital
  • Swedish Research Council
  • Syntonix Pharmaceuticals
  • Takeda Pharmaceutical
  • TauRx Therapeutics
  • TechnoPhage
  • Teikoku Pharma USA
  • Tekes
  • Teva Pharmaceutical
  • The Michael J. Fox Foundation
  • Theranostics Health
  • Theravance Biopharma
  • Thiel Foundation
  • Third Rock Ventures
  • Titan Pharmaceuticals
  • Toulouse University Hospital
  • Transition Therapeutics
  • Tri-CAP
  • Trigen Holdings
  • Tsinghua University
  • UCB Pharma
  • United Neuroscience
  • University Hospital of Lille
  • University of Aberdeen
  • University of California
  • University of Cologne
  • University of Florida
  • University of Lisbon
  • University of Miami
  • University of Nebraska
  • University of Puerto Rico
  • University of South Florida
  • University of Tbingen
  • University of Western Ontario
  • University of Zurich
  • Uppsala University
  • US WorldMeds
  • V ClinBio
  • venBio
  • Versant Ventures
  • Vertical Pharmaceuticals
  • Victor Company of Japan
  • Vinnova
  • Vivo Capital
  • Vivreon Biosciences
  • Voyager Therapeutics
  • Wellington Management
  • Woodford Patient Capital Trust
  • XenoPort
  • Xoc Pharmaceuticals
  • Yorkville Advisors
  • Ysios Capital
  • Zambon

For more information about this report visit

Media Contact:

Laura Wood, Senior Manager  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:

SOURCE Research and Markets

View Comments and Join the Discussion!